7:34AM ET 3/21/2023 MT NewswiresBioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $74 to $200, according to analysts polled by Capital IQ....
9:19AM ET 3/20/2023 MT NewswiresBioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $74 to $200, according to analysts polled by Capital IQ....
12:37AM ET 3/15/2023 MT NewswiresJean Jacques Bienaime, Director, Chief Executive Officer, on March 10, 2023, sold 23,000 shares in Biomarin Pharmaceutical (BMRN) for $2,107,800. Following...
9:52AM ET 3/07/2023 MT NewswiresBioMarin Pharmaceutical (BMRN) has an average outperform rating and price target range of $74 to $200, according to analysts polled by Capital IQ. (MT...